Our Impact Report details how we’re creating healthier futures.

Check it out
Skip to content

Brain Organoid Therapeutics (BOT)

Innovating the future of human tissue-based drug screens in neurology and oncology

Brain Organoid Therapeutics (BOT)

Brain Organoid Therapeutics (BOT) is a screening platform that leverages innovative human neural models in vitro to evaluate the efficacy and neurotoxicity of agents and therapeutics interacting with the nervous system.

Our expert team employs rigorous, state-of-the-art research methods to develop electrophysiologically-relevant neural models that closely mimic the human nervous system. Focused on scientific excellence and patient well-being, we collaborate with industry and academic researchers to provide our services and accelerate the translation of therapeutic breakthroughs while minimising neurotoxicity risks.. 

BOT is a collaboration between SAHMRI and Flinders University.

Visit the BOT website for more information

Specialised services

Preclinical modeling & screening 

  • Drug screening
  • Induced pluripotent stem cells (iPSCs)
  • 2D and 3D models in vitro
  • Disease models

Computational analysis

  • Machine learning and bioinformatics analysis

Functional characterisation & imaging 

  • Electrophysiology
  • Neuronal phenotyping
  • High content imaging

Clinical development 

  • Clinical trial support

Equipment

Automation & liquid handling

  • Janus automated liquid handler
  • Assist plus pipetting robot
  • 3D Bioprinters

Advanced imaging & metabolic profiling

  • High content confocal microscopes
  • incucute live cell imaging system
  • Seahorse real time cell metabolism analyzer

Electrophysiology Suite

  • Whole-cell patch clamping
  • Multi-electrode arrays
  • Calcium imaging

Computational infrastructure

  • Dedicated server (>400TB)
  • High performance computing systems (HPCs)

Get in touch